The efficacy and safety of anamorelin for patients with idiopathic pleuroparenchymal fibroelastosis (iPPFE)

Yasui Hideki0 个研究点目标入组 20 人开始时间: 2023年3月30日最近更新: 2024年4月23日

试验速览

暂无简介。

•Patients over 20 years old
•Patients diagnosed with iPPFE based on CT imaging and clinical findings
•Patients whose consent for this study has been obtained by signing a consent form

•Patients with a history of hypersensitivity to anamorelin
•Patients with congestive heart failure
•Patients with myocardial infarction or angina pectoris
•Patients with severe conduction defects (e.g., complete atrioventricular block)
•Patients who have received or are currently taking the following drugs within 1 week prior to the start of study treatment: clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir-containing products, cobicistat-containing products
•Patients with hepatic dysfunction of moderate severity or greater (Child-Pugh classification B and C)
•Patients with difficulty in oral intake of food due to obstruction of the gastrointestinal tract or other organic abnormality of the gastrointestinal tract
•Patients with diabetes mellitus who have poor glycemic control despite the use of oral diabetes medications or insulin
•Pregnant or nursing mothers
•Patients who are deemed inappropriate by the principal investigator (or sub-investigator)

发起方

Yasui Hideki